Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Nuvolone

Showing results (61-70 of 115) with videos related to

Pageof 12
Sort By:
Leukemia & Lymphoma|August 27, 2021
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosisGiovanni Palladini, Simone Celant, Paolo Milani, et al.
Hemasphere|March 25, 2025
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control studyClaudia Bellofiore, Marco Basset, Giuseppe Damiano Sanna, et al.
The FEBS Journal|September 5, 2021
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregationGiulia Mazzini, Stefano Ricagno, Serena Caminito, et al.
Journal of Molecular Biology|July 29, 2023
The Cryo-EM STRUCTURE of Renal Amyloid Fibril Suggests Structurally Homogeneous Multiorgan Aggregation in AL AmyloidosisSarita Puri, Tim Schulte, Antonio Chaves-Sanjuan, et al.
Disease Models & Mechanisms|July 25, 2025
Modeling immunoglobulin light chain amyloidosis in Caenorhabditis elegansMargherita Romeo, Maria Monica Barzago, Alessandro Corbelli, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 26, 2020
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patientsPaolo Milani, Faye Sharpley, Stefan O Schönland, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 19, 2026
Exploring light chain cardiotoxicity in AL amyloidosis: impact on hiPSC-derived cardiomyocyte activitySerena Calamaio, Anthony Frosio, Dario Melgari, et al.
Plos Pathogens|June 30, 2020
Genome-wide transcriptomics identifies an early preclinical signature of prion infectionSilvia Sorce, Mario Nuvolone, Giancarlo Russo, et al.
Cell Reports|September 23, 2020
The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory HomeostasisChiara Fucci, Massimo Resnati, Elena Riva, et al.
American Journal of Hematology|December 4, 2024
Feasibility of a Biomarker-Based Screening for Pre-Symptomatic AL Amyloidosis in Patients With Intermediate/High-Risk MGUSSilvia Mangiacavalli, Paolo Milani, Claudio Salvatore Cartia, et al.
Pageof 12

Showing results (61-70 of 115) with videos related to

Sort By:
Pageof 12
Leukemia & Lymphoma|August 27, 2021
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosisGiovanni Palladini, Simone Celant, Paolo Milani, et al.
Hemasphere|March 25, 2025
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control studyClaudia Bellofiore, Marco Basset, Giuseppe Damiano Sanna, et al.
The FEBS Journal|September 5, 2021
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregationGiulia Mazzini, Stefano Ricagno, Serena Caminito, et al.
Journal of Molecular Biology|July 29, 2023
The Cryo-EM STRUCTURE of Renal Amyloid Fibril Suggests Structurally Homogeneous Multiorgan Aggregation in AL AmyloidosisSarita Puri, Tim Schulte, Antonio Chaves-Sanjuan, et al.
Disease Models & Mechanisms|July 25, 2025
Modeling immunoglobulin light chain amyloidosis in Caenorhabditis elegansMargherita Romeo, Maria Monica Barzago, Alessandro Corbelli, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 26, 2020
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patientsPaolo Milani, Faye Sharpley, Stefan O Schönland, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 19, 2026
Exploring light chain cardiotoxicity in AL amyloidosis: impact on hiPSC-derived cardiomyocyte activitySerena Calamaio, Anthony Frosio, Dario Melgari, et al.
Plos Pathogens|June 30, 2020
Genome-wide transcriptomics identifies an early preclinical signature of prion infectionSilvia Sorce, Mario Nuvolone, Giancarlo Russo, et al.
Cell Reports|September 23, 2020
The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory HomeostasisChiara Fucci, Massimo Resnati, Elena Riva, et al.
American Journal of Hematology|December 4, 2024
Feasibility of a Biomarker-Based Screening for Pre-Symptomatic AL Amyloidosis in Patients With Intermediate/High-Risk MGUSSilvia Mangiacavalli, Paolo Milani, Claudio Salvatore Cartia, et al.
Pageof 12